Trial reportMolecules (Basel, Switzerland)2019
Dosimetry of
Trial report in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- Joint EANM/SNMMI procedure guideline for the use ofEuropean journal of nuclear medicine and molecular imaging · 2023Guideline
- Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.European journal of nuclear medicine and molecular imaging · 2026Trial
- The Impact of Monosodium Glutamate onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Dosimetry and safety ofEuropean journal of nuclear medicine and molecular imaging · 2020Trial
- SUVMolecular imaging and biology · 2020Trial
- Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer WithAsia-Pacific journal of clinical oncology · 2026Article
- Drug interactions involving therapeutic radiopharmaceuticals: a systematic review.EJNMMI radiopharmacy and chemistry · 2026Review
- Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry inMolecular imaging and biology · 2025Article
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report.Radiology case reports · 2025Article
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorbed dose inEJNMMI physics · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?Biomedicines · 2024Review
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Article
- Predicting the effect of different folate doses on [EJNMMI research · 2023Article
- Metal-Based Radiopharmaceuticals in Inorganic Chemistry.Molecules (Basel, Switzerland) · 2023Article
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Radio-ligand therapy (RLT) with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.